It's been a sad week for Jazz Pharmaceuticals plc (NASDAQ:JAZZ), who've watched their investment drop 16% to US$98.41 in the week since the company reported its first-quarter result. It was a pretty negative result overall, with revenues of US$898m missing analyst predictions by 8.7%. Worse, the business reported a statutory loss of US$1.52 per share, a substantial decline on analyst expectations of a profit. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NasdaqGS:JAZZ Earnings and Revenue Growth May 9th 2025

Following the latest results, Jazz Pharmaceuticals' 19 analysts are now forecasting revenues of US$4.23b in 2025. This would be a modest 4.1% improvement in revenue compared to the last 12 months. The company is forecast to report a statutory loss of US$6.09 in 2025, a sharp decline from a profit over the last year. Before this earnings report, the analysts had been forecasting revenues of US$4.29b and earnings per share (EPS) of US$9.51 in 2025. So despite reconfirming their revenue estimates, the analysts are now forecasting a loss instead of a profit, which looks like a definite drop in sentiment following the latest results.

Check out our latest analysis for Jazz Pharmaceuticals

As a result, there was no major change to the consensus price target of US$184, with the analysts implicitly confirming that the business looks to be performing in line with expectations, despite higher forecast losses. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Jazz Pharmaceuticals analyst has a price target of US$230 per share, while the most pessimistic values it at US$125. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Jazz Pharmaceuticals' past performance and to peers in the same industry. It's pretty clear that there is an expectation that Jazz Pharmaceuticals' revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 5.5% growth on an annualised basis. This is compared to a historical growth rate of 13% over the past five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 8.3% per year. Factoring in the forecast slowdown in growth, it seems obvious that Jazz Pharmaceuticals is also expected to grow slower than other industry participants.

Story Continues

The Bottom Line

The biggest low-light for us was that the forecasts for Jazz Pharmaceuticals dropped from profits to a loss next year. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at US$184, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Jazz Pharmaceuticals going out to 2027, and you can see them free on our platform here..

Don't forget that there may still be risks. For instance, we've identified  3 warning signs for Jazz Pharmaceuticals that you should be aware of.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments